How many drugs treat Candidiasis of the esophagus?

Drug Landscape tracks 7 marketed treatments for Candidiasis of the esophagus (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/candidiasis-of-the-esophagus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Candidiasis of the esophagus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Candidiasis of the esophagus (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Candidiasis of the esophagus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Eraxis	ANIDULAFUNGIN	Vicuron Holdings	Echinocandin Antifungal [EPC]		2006-01-01
Mycamine	MICAFUNGIN	Teva Pharms Usa Inc	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2005-01-01
Cancidas	CASPOFUNGIN	Merck & Co.	Echinocandin Antifungal	ATP-binding cassette sub-family G member 2	2001-01-01
Sporanox	itraconazole	Sebela Ireland Ltd	Azole Antifungal [EPC]	C-X-C chemokine receptor type 1	1992-01-01
Diflucan	fluconazole	Pfizer Inc.	Azole Antifungal [EPC]	Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase	1990-01-29
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Fluconazol	Fluconazol	Azienda Sanitaria-Universitaria Integrata di Udine		Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Astellas Pharma · 1 drug in Candidiasis of the esophagus
Azienda Sanitaria-Universitaria Integrata di Udine · 1 drug in Candidiasis of the esophagus
Merck & Co. · 1 drug in Candidiasis of the esophagus
Pfizer Inc. · 1 drug in Candidiasis of the esophagus
Sebela Ireland Ltd · 1 drug in Candidiasis of the esophagus
Teva Pharms Usa Inc · 1 drug in Candidiasis of the esophagus
Vicuron Holdings · 1 drug in Candidiasis of the esophagus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Candidiasis of the esophagus:

Cite this brief

Drug Landscape (2026). Candidiasis of the esophagus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/candidiasis-of-the-esophagus. Accessed 2026-06-10.

Candidiasis of the esophagus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing